{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:26:05Z","timestamp":1784366765517,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.leukres.2023.107032","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T12:11:44Z","timestamp":1675685504000},"page":"107032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5270-104X","authenticated-orcid":false,"given":"Richa","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Morlote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-5683","authenticated-orcid":false,"given":"Smita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2023.107032_bib1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMra1607548","article-title":"McClain KL. Langerhans-cell histiocytosis","volume":"379","author":"Allen","year":"2018","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.leukres.2023.107032_bib2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood.2019000934","article-title":"Langerhans cell histiocytosis","volume":"135","author":"Rodriguez-Galindo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107032_bib3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107032_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Disco"},{"key":"10.1016\/j.leukres.2023.107032_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2023.107032_bib6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2023.107032_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/onco.13541","article-title":"Efficacy of BRAF-inhibitor therapy in BRAF(V600E) -mutated adult langerhans cell histiocytosis","volume":"25","author":"Hazim","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2023.107032_bib8","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107032_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28712","article-title":"Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib","volume":"67","author":"Messinger","year":"2020","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.leukres.2023.107032_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjh.14818","article-title":"Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes","volume":"182","author":"Goyal","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107032_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cam4.1844","article-title":"Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies","volume":"8","author":"Ma","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.leukres.2023.107032_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/1097-0142(19930201)71:3<865::AID-CNCR2820710334>3.0.CO;2-0","article-title":"Association of Langerhans cell histiocytosis with malignant neoplasms","volume":"71","author":"Egeler","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2023.107032_bib13","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2023.107032_bib14","first-page":"107","article-title":"Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood","author":"Matasar","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2023.107032_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","article-title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study","volume":"21","author":"Suh","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2023.107032_bib16","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.30739","article-title":"Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era","volume":"123","author":"Howlader","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2023.107032_bib17","doi-asserted-by":"crossref","first-page":"E464","DOI":"10.1002\/ajh.26377","article-title":"A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: comparison with data from a Mayo Clinic single institutional series","volume":"96","author":"Smith","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107032_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2023.107032_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13541","article-title":"Efficacy of BRAF-inhibitor therapy in BRAF(V600E) -mutated adult langerhans cell histiocytosis","author":"Hazim","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2023.107032_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/mpo.2950230204","article-title":"Acute leukemia in association with Langerhans cell histiocytosis","volume":"23","author":"Egeler","year":"1994","journal-title":"Med Pedia Oncol."},{"key":"10.1016\/j.leukres.2023.107032_bib21","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/1097-0142(19931215)72:12<3723::AID-CNCR2820721226>3.0.CO;2-Y","article-title":"Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis","volume":"72","author":"Horibe","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2023.107032_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/(SICI)1097-0215(19970328)71:1<9::AID-IJC3>3.0.CO;2-Y","article-title":"Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations","volume":"71","author":"Haupt","year":"1997","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.leukres.2023.107032_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0303-6987.2006.00299.x","article-title":"Langerhans cell histiocytosis associated with myelodysplastic syndrome in adults","volume":"33","author":"Billings","year":"2006","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.leukres.2023.107032_bib24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamadermatol.2020.0544","article-title":"Association between high-grade myelodysplastic syndrome and cutaneous langerhans cell histiocytosis suggested by next-generation sequencing","volume":"156","author":"Khurana","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.leukres.2023.107032_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.leukres.2023.107032_bib26","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107032_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0889-8588(05)70516-5","article-title":"The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-malignancy study group of the histiocyte society","volume":"12","author":"Egeler","year":"1998","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2023.107032_bib28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMoa012087","article-title":"Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults","volume":"346","author":"Vassallo","year":"2002","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2023.107032_bib29","first-page":"59","article-title":"Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort","author":"Benattia","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.leukres.2023.107032_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(05)70211-4","article-title":"Clonal relationship between precursor T-lymphoblastic leukaemia\/lymphoma and Langerhans-cell histiocytosis","volume":"6","author":"Feldman","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2023.107032_bib31","article-title":"Langerhans cell histiocytosis developing acute lymphoblastic leukemia","volume":"10","author":"Zhang","year":"2022","journal-title":"SAGE Open Med Case Rep."},{"key":"10.1016\/j.leukres.2023.107032_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ajh.21044","article-title":"Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1","volume":"83","author":"Rodig","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107032_bib33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.leukres.2009.07.025","article-title":"Acute myeloid leukemia and Langerhans' cell histiocytosis: multiple theories for an unusual presentation","volume":"34","author":"Ghosn","year":"2010","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2023.107032_bib34","first-page":"163","article-title":"Long-term sequelae of histiocytosis X","volume":"3","author":"Komp","year":"1981","journal-title":"Am. J. Pedia Hematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107032_bib35","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/cncr.28763","article-title":"Infections among long-term survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study","volume":"120","author":"Perkins","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2023.107032_bib36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1067\/mpd.2001.111331","article-title":"A randomized trial of treatment for multisystem Langerhans' cell histiocytosis","volume":"138","author":"Gadner","year":"2001","journal-title":"J. Pedia"},{"key":"10.1016\/j.leukres.2023.107032_bib37","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","article-title":"Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification","volume":"111","author":"Gadner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107032_bib38","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107032_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13023-015-0249-2","article-title":"The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study","volume":"10","author":"Tazi","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.leukres.2023.107032_bib40","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/ATVBAHA.118.310803","article-title":"Hypoalphalipoproteinemia and BRAF(V600E) mutation are major predictors of aortic infiltration in the erdheim-chester disease","volume":"38","author":"Cohen-Aubart","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.leukres.2023.107032_bib41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.2020008965","article-title":"CHIPping away at Erdheim-Chester disease","volume":"137","author":"Goyal","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107032_bib42","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood.2020005101","article-title":"High frequency of clonal hematopoiesis in Erdheim-Chester disease","volume":"137","author":"Cohen Aubart","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107032_bib43","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3109\/10428194.2010.525724","article-title":"Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases","volume":"51","author":"Bazzeh","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2023.107032_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107032_bib45","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2018-07-862607","article-title":"Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma","volume":"133","author":"Opstal-van Winden","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107032_bib46","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1158\/1078-0432.CCR-16-0610","article-title":"Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors","volume":"23","author":"Sherborne","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2023.107032_bib47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrclinonc.2013.83","article-title":"Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma","volume":"10","author":"Gibney","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107032_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw. Open"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:11Z","timestamp":1758935051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":48,"alternative-id":["S0145212623000176"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107032","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107032"}}